Dr. John Steeves, Co-Chair of Spinal Cord Outcomes Partnership Endeavor, to Discuss Clinical Foundations for Endpoints and Outcome Measures in Spinal Cord Injury Trials
Webcast Scheduled at 9:30 a.m. ET on May 8, 2015
MENLO PARK, Calif., May 6, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that the Company will host a meeting with the investment community to review the clinical development strategy for AST-OPC1 (oligodendrocyte progenitor cells) in spinal cord injury on Friday, May 8, 2015. Topics will include the current Phase 1/2a clinical trial and future planned clinical activities for AST-OPC1.
The program will include presentations by Asterias' President and Chief Executive Officer Pedro Lichtinger, President of Research and Development Jane S. Lebkowski, Ph.D., and Chief Translational Officer Edward D. Wirth, III, M.D., Ph.D. In addition, John Steeves, Ph.D., Co-Chair of the Spinal Cord Outcomes Partnership Endeavor (SCOPE) and Professor of International Collaboration on Repair Discoveries (ICORD), will discuss clinical foundations for the endpoints and outcome measures in spinal cord injury trials.
A live webcast of the presentations will begin at 9:30 a.m. ET and the webcast will conclude by 12:00 p.m. ET. The live webcast of the event will be available on the Company's website at: http://asteriasbiotherapeutics.com/events-presentations/. An archived webcast will be available at the same website following the conclusion of the meeting.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) is a leading biotechnology company in the emerging field of regenerative medicine. The Company's core technologies center on pluripotent stem cells, which are characterized by the ability to become all cell types in the human body. Asterias is focused on developing therapies based on pluripotent stem cells to treat diseases or serious injuries in several medical areas where there is high unmet medical need and without adequate available therapies. Asterias' two therapeutic programs, AST-OPC1 (oligodendrocyte progenitor cells) for spinal cord injuries and AST-VAC2 (antigen-presenting allogeneic dendritic cells) for lung cancer, are based on the Company's proprietary technology platforms of Pluripotent Stem Cells and Allogeneic Dendritic Cell Immunotherapy, respectively. AST-OPC1 is currently in a Phase 1/2a clinical trial. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.
Forward Looking Statements
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias' filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.
SOURCE Asterias Biotherapeutics, Inc.